SIGNATURES
The present trial protocol was subject to critical review and has been approved in the present version by the persons undersigned. The information contained is consistent with:
-the current risk-benefit assessment of the investigational medicinal product -the moral, ethical, and scientific principles governing clinical research as set out in the applicable version of Declaration of Helsinki and the principles of GCP. The investigator will be supplied with details of any significant or new finding including Adverse Events relating to treatment with the investigational medicinal product. EudraCT: 2007-005537-11 _____________________________________________________________________________________________  No other simultaneous anti-neoplastic treatment or radiation during the study and 1 months before enrolment  Sufficient general condition (Lansky Score > 50%)  Life expectancy > 3 months  Liver enzymes (ALT or AST) < 5x upper limit of normal reference value, bilirubin and creatinine < 3x upper limit of normal reference value  Solid tumors: leukocytes > 2000/µl, thrombocytes > 50.000/µl and adequate bone marrow function to permit evaluations of haematopoietic toxicity  Normal electrocardiogram  No common toxicity criteria (CTC) grade 3 or 4 toxicity from previous treatment  Written informed consent of the legal representatives and the patient if the patient is able to understand the study situation and to give consent (must be available before enrolment in the trial)  Women with childbearing potential agree to use adequate contraception or to abstain from heterosexual activity throughout the study, starting with Visit 1.  Sexually active male patient agrees to use an adequate method of contraception for the duration of the study. 
Principal Investigator

Objectives
Primary
To determine a safe dose recommended (SDR) for the routine application of oral vorinostat (involving dose escalation) in children and adolescents (3-18 years) with relapsed/refractory solid tumor, lymphoma or leukemia. A SDR is defined as the highest dose with no ≥ grade 3 toxicity according to CTC criteria in no more than 1/50 patient in this study (for details refer chapter 2.1).
Secondary
To determine the  pharmacokinetics and the distribution of individual maximum tolerated doses (MTD), which is the maximum dose with no grade 3 or 4 toxicity according to CTC criteria.  antitumor effectiveness of vorinostat as measured by treatment response rate.
Response will be evaluated in each patient three months after start of treatment with the individual MTD. Version: Final 2.3 09.06.2011 EudraCT: 2007-005537-11 _____________________________________________________________________________________________  association of the histone deacetylase (HDAC)-inhibiting activity with the dose administered, toxicity, and treatment response.  feasibility and safety  duration of response in responding patients. Additional biomarker studies for the prediction of vorinostat response (IL-6, IL-10, BMP4) induction, basal histone acetylation level) will be performed.
Vorinostat in Children
Trial Design
Open-label single-arm, intra-patient dose escalation, multi-centre, national Phase I/II clinical trial.
Investigational Medicinal Product(s)
Vorinostat, SAHA (suberoylanilide hydroxamic acid) Suspension at 50mg/ml oral administration qd (once per day) with food Capsules at 100mg oral administration qd (once per day) with food Starting dose: 180 mg/m ² /d, individual dose escalation every 2 weeks until MTD is reached. Thereafter each patient will receive a maintenence therapy at this individually determined MTD for at least 3 months. Minimum dose: 30 mg/m²/d. Maximum dose: 580 mg/m²/d. Responding patients: continuation of vorinostat for a maximum of 9 months or withdrawal from study for other reasons.
Sample Size
The sample size calculation in this study was based on the accuracy requirements for the toxicity rate associated with the safe dose for the routine application. 50 pediatric patients ≥ 3 years will be included in the trial. If dose limiting toxicity (DLT) (i.e. ≥ grade 3 toxicity) is observed at a given dose d in 1/50 patients (this defines the safe dose for routine application) then the 95% confidence interval for the true rate r of DLT at this dose is [0.05;10.65]%. Additionally, this is a feasible number of patients to be recruited by the participating trial centers within 2 years.
Statistical Analysis
Estimation of toxicity rates with 95%-CI . 
Trial Duration and Dates
